A1. FLUENCE ENERGY (NASDAQ: FLNC)

Price (Mar 2026): ~$18.46 | Market Cap: ~$2.8B

Setup

Fluence is the leading pure-play utility-scale battery energy storage integrator, a JV-originated company (Siemens + AES) with global reach. Q1 FY2026 revenue surged 154% YoY to $475M, and it reported a record backlog of $5.5B — a ~12% YoY pipeline increase to $23.4B total. The company is now a credible large-project deployments engine at exactly the moment European and US grid investment is escalating post-Iberian blackout. FY2026 guidance: $3.2B–$3.6B revenue, targeting adjusted EBITDA of $40–$60M (first-ever EBITDA positive full year). ARR target of ~$180M from its Mosaic OS software layer is a high-margin stream building alongside the integration business.

Catalysts

• Record backlog converts to revenue through FY2026–FY2027; US orders >$500M in Q1 alone
• European regulatory response to April 2025 blackout driving procurement urgency (Spain BESS targets far below actual installed base)
• Mosaic OS software ARR expansion — recurring revenue derisks lumpiness of project cycles
• Potential gross margin re-rating if two loss-generating international projects (flagged in Q1) are resolved

Risk

• Q1 gross margin was only 4.9% GAAP (5.6% adjusted), well below full-year guide of 11–13%; execution on international projects is the critical near-term risk
• ASPs declined 26% YoY to $192/kWh, reflecting pricing pressure from Chinese BESS competition
• Stock down ~37% in past month post-Q1, creating opportunity but also signaling execution concern
• Hold consensus from 18 analysts (4 buy / 12 hold / 4 sell) — conviction is not high on the Street

Valuation

~0.8x FY2026 revenue guide midpoint ($3.4B). If EBITDA target is hit, stock trades at ~55x EBITDA — expensive for a hardware integrator, but software ARR buildout warrants a premium. Price target range: $9 (bear, Strouse/JPM) to $32 (bull, Goldman/Lee). Median consensus: $19.00. Current price represents a potential ~60% upside to median target.

A2. ITRON (NASDAQ: ITRI)

Price (Mar 2026): ~$92.69 | Market Cap: ~$4.2B

Setup

Itron is the dominant smart metering, grid edge intelligence, and distribution automation platform for utilities globally. The company recently created a dedicated "Resiliency Solutions" segment following strategic acquisitions, directly positioning itself against the grid stability problem highlighted by the Iberian blackout. Q4 2025 results beat estimates ($2.46 EPS vs. $2.19 consensus), and FY2026 guidance of $2.35B–$2.45B revenue and EPS of $5.75–$6.25 brackets consensus. With 10 analyst Buy ratings and an average 12-month price target of $136.80, the stock is trading ~32% below the consensus target after pulling back from a 52-week high of $142.

Catalysts

• Resiliency Solutions segment rollout — directly monetizes grid hardening post-Iberian event
• US grid modernization spending (IRA-driven) funnels through utility capex budgets in 2026–2027
• European interconnection and grid intelligence investment cycle (ENTSO-E recommendations)
• Grid Edge AI/DER management unlocks higher-margin software attach rates on installed meter base
• Beat-and-raise cadence established (Q4 EPS beat by $0.27)

Risk

• Stock at 52-week low — market is pricing in macro/tariff headwinds on utility capex
• Utility procurement cycles are long; revenue guidance implies only modest growth from current run-rate
• $4.2B market cap puts it at the top of the target range; liquidity is good but re-rating requires sustained beats
• Acquisitions (Resiliency segment) may compress near-term margins during integration

Valuation

~1.7x FY2026 revenue; ~15x FY2026 EPS midpoint ($6.00). For a profitable, growing grid infrastructure company with software/services mix, this is a modest multiple. EPS-based valuation is the more compelling frame: PEG ratio suggests the stock is undervalued at current levels given guided EPS growth. Trading at ~33% discount to 52-week highs and ~32% below analyst consensus.

A3. STEM, INC. (NYSE: STEM)

Price (Mar 2026): ~$10.80 | Market Cap: ~$82M

Setup

Stem has executed a deliberate pivot from hardware-heavy energy storage integration to a software-centric AI platform (PowerTrack Optimizer) for managing distributed energy assets. The result: FY2025 non-GAAP gross margin improved to 46% (from -8% in 2024), with software/services/edge hardware revenue of $141.4M growing 25% YoY. FY2026 guidance targets $10–$15M adjusted EBITDA — the company's first-ever EBITDA positive guidance. German deployment win (Everyray, via PowerTrack) validates European addressable market expansion. Market cap at ~$82M implies investors are almost entirely discounting the software platform.

Catalysts

• First EBITDA positive year (FY2026 guide) — a binary inflection for a stock that traded near zero in 2025
• ARR target of $65–$70M by year-end 2026 at 80%+ gross margins
• AI data center operators adopting energy optimization software as power cost becomes strategic
• European grid instability post-Iberia accelerating DER management software procurement
• Extremely low market cap creates explosive upside leverage if software narrative is accepted

Risk

• Market cap is now below $100M — well below intended screen floor of $300M. Illiquid and speculative; position sizing must be limited
• Revenue guide of $140–$190M has a wide range; downside scenario is still a hardware-oriented miss
• Hardware project lumpiness could overwhelm software margin progress in any given quarter
• Management credibility: the company has repeatedly missed execution targets in prior years
• Avoid as a primary position; flag as a high-risk/high-reward satellite holding only

Valuation

~0.5x FY2026 revenue midpoint. Software ARR alone, if sustained at $65–$70M with 80% gross margins, would justify a $200–$400M market cap at SaaS-sector comps. Near-term trading inefficiency appears significant.

A4. NEXTPOWER INC. (NASDAQ: NXT) — formerly Nextracker — Watch List

Price (Mar 2026): ~$116.91 | Market Cap: ~$17B

Setup

Nextpower (rebranded from Nextracker in November 2025) is repositioning from the world's #1 solar tracker manufacturer into an integrated power conversion and grid-edge technology platform. The rebranding itself signals a strategic shift — the company is building utility-scale power conversion systems (first shipments expected 2026) and targeting ~one-third of FY2030 revenue from non-tracker products. Revenue has grown from $1.9B (FY2023) to ~$3.4B TTM (Sept 2025) with 150 GW of systems shipped globally. The AI data center power build-out is the primary near-term driver; hyperscalers need power delivery infrastructure, not just generation.

Setup Qualifier

At $17B market cap this exceeds the $10B screen ceiling, but it is flagged as a Watch — the company's strategic pivot places it in a category that did not exist six months ago (grid-edge power conversion), and the market may not yet be pricing the new business mix correctly.

Catalysts

• First-shipment milestone for utility-scale power conversion systems (2026H2)
• AI/data center site power integration deals (hyperscaler procurement pipeline)
• FY2030 revenue target of $4.8B–$5.6B — if non-tracker share builds, multiple re-rates upward
• Post-rebranding analyst coverage shift (new coverage initiations likely)

Risk

• $17B market cap — outside screen bounds; current valuation prices in significant execution
• Power conversion segment is unproven; revenue contribution is minimal today
• Tariff/trade risk on hardware components
• Investor base anchored to solar narrative; pivot may cause confusion and multiple compression before re-rating

~5x TTM revenue — premium to hardware peers but supported by tracker market dominance and growth visibility. Flagged as Watch List, not an active recommendation within this screen's constraints.

B1. TEMPUS AI (NASDAQ: TEM)

Price (Mar 2026): ~$46.96 | Market Cap: ~$8.4B

Setup

Tempus AI is the most clinically credentialed AI-in-healthcare company now trading publicly, combining genomics data (world's largest structured oncology dataset), multi-FDA-cleared AI diagnostics, and an emerging life sciences data licensing business. Multiple FDA clearances in 2025: RNA-based Tempus xR IVD (510k, Sept 2025) for oncology; AI-ECG tool for heart failure detection. FY2025 Genomics revenue grew 117.2% YoY to $252.9M; total revenue grew 84.7% YoY. FY2026 analyst consensus: ~$283M revenue (one source), though the actual figure is likely higher when annualizing the run-rate. The stock has pulled back sharply from a 52-week high of $104.32 to ~$47 — nearly a 55% drawdown — creating a potential entry point.

Catalysts

• FDA clearances for additional AI diagnostic products (cardiology, radiology pipeline)
• Companion diagnostics (CDx) partnerships with major pharma; each CDx deal carries milestone + royalty economics
• CMS reimbursement expansion for AI-assisted genomic testing — a multi-billion dollar addressable unlock
• Life sciences data licensing (recurring, high-margin) scaling as dataset moat compounds
• 43.77% forecast revenue growth rate vs. sector average of 11.99%

Risk

• Not yet profitable — sustained losses require capital markets confidence; dilution risk
• Stock at 52-week low range; sentiment has deteriorated from peak AI-healthcare enthusiasm
• Competition from large health system in-house genomics programs and Foundation Medicine (Roche)
• $8.4B market cap is at the top of the $200M–$5B screen range — slightly outside bounds
• Revenue figure discrepancy in available data suggests Street is modeling different segments

Valuation

~30x FY2026 revenue — premium, but Tempus is the rare clinical AI company with multiple cleared products and proprietary data network effects. Bull case price target: $100 (Goldman, ~113% upside from current). Consensus: $78–$79 (~65% upside). Risk-adjusted: the pullback from $104 to $47 has materially improved the entry point even as the fundamental trajectory strengthened.

B2. VERACYTE (NASDAQ: VCYT)

Market Cap: ~$2.8B

Setup

Veracyte is a profitable genomic diagnostics company with an established oncology franchise (Decipher prostate cancer test, thyroid, kidney) that is now executing a deliberate expansion into two high-value new categories: (1) TrueMRD — a whole-genome sequencing + AI minimal residual disease (MRD) detection platform, first launch planned H1 2026 in muscle-invasive bladder cancer; (2) Prosigna expansion into new breast cancer indications. The company appointed a new AI-focused CTO in March 2026, signaling deepening commitment to AI as a competitive moat. FY2025 Q4 showed 19% revenue growth; FY2026 guidance: 10–13% revenue growth, adjusted EBITDA margin ~25%.

Catalysts

• TrueMRD H1 2026 commercial launch — bladder cancer is an underpenetrated MRD market; first-mover advantage
• Prosigna breast cancer indication expansion — incremental revenue from existing commercial infrastructure
• ASCO GU 2026 data presentations (15 studies on Decipher) — clinical validation compounds ordering physician confidence
• AI CTO appointment signals product velocity improvement; new platforms in development
• Profitability is established (~25% EBITDA margin) — capital allocation flexibility for BD

Risk

• TrueMRD is a new modality; commercial launch execution risk (lab build-out, payer coverage timelines)
• 10–13% revenue growth is below what the Street typically rewards; multiple is constrained unless MRD ramps materially
• CMS coverage for MRD testing in solid tumors is not yet established — reimbursement timeline is the key gating factor
• Genomics testing space has competitive intensity (Foundation Medicine, Guardant, NeoGenomics)

Valuation

~5.4x FY2026 revenue estimate (~$515–$525M). For a profitable, 10–13% grower with two near-term product launches, this is reasonable but not compelling on the base business alone. The MRD call option is the upside case — if TrueMRD gains traction and reimbursement, the revenue trajectory re-rates materially in FY2027. Price target consensus: ~$35–$40 range per available data.

B3. PHREESIA (NYSE: PHR)

Price (Mar 2026): ~$11.48 | Market Cap: ~$692M

Setup

Phreesia is a SaaS platform for patient intake, registration, and engagement — a critical piece of healthcare administrative infrastructure used by 4,520+ ambulatory healthcare sites (AHSCs). The story in March 2026 is a decisive profitability inflection: Phreesia achieved its first-ever net income positive quarter in Q2 FY2026, four consecutive quarters of positive free cash flow, and in Q3 FY2026 (ended Oct 2025) delivered a record 24% adjusted EBITDA margin (up 15 ppts YoY). FY2027 guidance introduced: $545M–$559M revenue (+14–16% growth), $125M–$135M adjusted EBITDA — the AccessOne acquisition (patient financing/payment management, closed Nov 2025) adds a complementary revenue layer. Stock is near a 52-week low of ~$11.58 despite the profitability breakthrough.

Catalysts

• FY2027 guidance is credible and above prior expectations — inflection is now guided, not just implied
• AccessOne integration: $110M acquisition brings patient payment management into the platform; cross-sell to existing 4,520 AHSCs
• EBITDA margin expansion from 24% (Q3 FY26) toward 25–27% range — operating leverage is real and now demonstrated
• Revenue per AHSC growing 6% YoY ($26,622) — indicates upsell velocity, not just new-logo dependency
• Near 52-week lows creates an asymmetric setup: downside appears limited, upside ~140% to consensus target

Risk

• Macroeconomic sensitivity: ambulatory healthcare spending can compress during economic downturns
• AHSC net add growth (+7% YoY) is decelerating; if AHSCs churn, leverage math inverts
• AccessOne bridge loan ($110M, 364-day) matures — refinancing risk in a higher-rate environment
• Market cap at $692M is near the bottom of the screen range; thin liquidity on large positions
• The stock is down ~65% from 52-week highs despite improved fundamentals — understanding why the market is skeptical is important pre-investment

Valuation

~1.3x FY2027 revenue guide midpoint. For a SaaS company with 24% EBITDA margins and 14–16% guided revenue growth, this is historically very cheap. Consensus analyst price target: $28.05 (20 analysts, 0 sell ratings) vs. current price of ~$11.48 — implies ~144% upside. The disconnect between analyst consensus and current price suggests a catalyst is needed to close the gap.

B4. PRIVIA HEALTH (NASDAQ: PRVA)

Price (Mar 2026): ~$21.22 | Market Cap: ~$2.6B

Setup

Privia Health is a physician enablement company — it operates as the technology and management services layer for large primary-care-centric physician networks across 24 US states. Think of it as a SaaS-enabled MSO: Privia provides revenue cycle management, payer contracting, data analytics, and practice operations to affiliated physicians while aggregating them into risk-bearing entities. FY2025 Q4 EPS of $0.99 dramatically beat the $0.04 consensus; Q3 2025 revenues grew 32.5% YoY to $580.4M with operating income up ~150% — operational leverage is visible and accelerating. FY2026 guidance: $2.35B–$2.45B revenue (3.7% above analyst estimates), EBITDA of ~$150M. The company just won the 2026 HFMA MAP Award for Revenue Cycle Excellence for the ninth time in ten years.

Catalysts

• Value-based care (VBC) contract wins: Privia's risk-bearing entity model benefits from CMS VBC program expansion
• Geographic expansion into new states — organic growth engine for affiliated physician headcount
• Operating leverage: Q4 EPS beat of $0.99 vs. $0.04 consensus signals margins are improving structurally
• Healthcare consolidation trend: independent practices seeking technology infrastructure are a natural acquisition funnel
• Stock down ~10% YTD in 2026 despite strong earnings — potential re-rating catalyst from next earnings beat

Risk

• Business model complexity: Privia captures a percentage of affiliated physician revenue — growth depends on physician acquisition and retention
• CMS reimbursement rate changes or VBC program alterations are existential risks for the economics
• CFO share sales in March 2026 (flagged in news) — minor but noteworthy insider signal
• Competition from Aledade, Agilon Health, and health system-employed physician models

Valuation

~1.1x FY2026 revenue; ~17x FY2026 EBITDA midpoint ($150M). This is modest for a high-growth physician enablement platform. Strong Buy consensus from analysts; average price target of $30.80–$31.00 vs. current price of $21.22 — implies ~45–48% upside. The beat in Q4 EPS may be the most significant signal in this screen: the company has demonstrated that its unit economics are better than the Street modeled.